ALPS Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

ALPS Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-46,259	Closed	-$1.85M	–	1024
2023 Q1	$1.85M	Sell	46,259 -1,265	-3%	-$54.3K	0.02%	303
2022 Q4	$2.2M	Buy	+47,524	New	+$1.87M	0.02%	283
2017 Q4	–	Sell	-41,814	Closed	-$2.23M	–	876
2017 Q3	$2.23M	Buy	41,814 +3,649	+10%	+$216K	0.02%	180
2017 Q2	$2.37M	Buy	38,165 +2,267	+6%	+$137K	0.02%	173
2017 Q1	$2.43M	Sell	35,898 -3,366	-9%	-$257K	0.02%	165
2016 Q4	$2.76M	Sell	39,264 -11,010	-22%	-$781K	0.02%	161
2016 Q3	$3.57M	Sell	50,274 -4,542	-8%	-$290K	0.03%	158
2016 Q2	$2.68M	Buy	54,816 +11,142	+26%	+$721K	0.02%	156
2016 Q1	$2.77M	Sell	43,674 -7,485	-15%	-$490K	0.03%	138
2015 Q4	$5.74M	Sell	51,159 -8,479	-14%	-$848K	0.06%	116
2015 Q3	$57.4K	Buy	59,638 +24,008	+67%	+$2.75M	0.06%	105
2015 Q2	$3.65M	Buy	35,630 +18,326	+106%	+$1.42M	0.03%	134
2015 Q1	$1.07M	Buy	+17,304	New	+$961K	0.01%	183

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ALPS Advisors's RARE Position: Q2 2023 in Review

ALPS Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2023, closing a stake of 46,259 shares — an estimated $1.85M sold.

ALPS Advisors first reported a position in RARE in Q1 2015 and held it in 13 quarters. The position peaked at $5.74M in Q4 2015. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

ALPS Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2023 after selling out during the quarter.
ALPS Advisors sold 46,259 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $1.85M.
ALPS Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 13 quarters.
ALPS Advisors's Ultragenyx Pharmaceutical position peaked at $5.74M in Q4 2015.
242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.